BRCA1 and ovarian serous adenocarcinoma: Relative de novo sensitivity to artesunate was evaluated in a panel of human high-grade serous ovarian cancer cell lines including CAOV3, OVCAR3, OV-90, and BRCA1-null UWB1.289 cells.